Efficacy and safety of tranexamic acid in bimaxillary orthognathic surgery: systematic review and network meta-analysis of randomized controlled trials.
J Felipe Junior, V R Barbosa de Menezes, A J Barbosa de França et al.
✦ AI-curated · Sources linked
In 30 seconds
This systematic review and network meta-analysis evaluated the efficacy and safety of intravenous tranexamic acid (TXA) in reducing blood loss during bimaxillary orthognathic surgery. Analyzing five randomized controlled trials with 353 participants, the study found that a 20 mg/kg dose of TXA significantly reduced intraoperative blood loss compared to placebo, while no significant differences in transfusion needs or thromboembolic risk were observed.
Key findings
- The 20 mg/kg dose of TXA significantly reduced intraoperative blood loss compared to placebo.
- The 10 and 15 mg/kg doses showed a reduction in blood loss, but this was not statistically significant.
- No significant reduction in transfusion needs compared to placebo was observed.
- No significant difference in thromboembolism risk was found between TXA regimens.
Why it matters
Understanding the efficacy and safety of TXA in surgical settings is crucial for optimizing patient outcomes and minimizing complications related to blood loss and transfusions during major procedures.
What to keep in mind
The study faced methodological heterogeneity and a limited number of trials, which restricts the ability to draw firm conclusions on optimal dosing.